Provided by Tiger Trade Technology Pte. Ltd.

Neurocrine Biosciences

157.22
+1.000.64%
Post-market: 157.220.00000.00%19:59 EDT
Volume:785.55K
Turnover:123.63M
Market Cap:16.04B
PE:23.04
High:159.19
Open:158.00
Low:156.57
Close:156.22
52wk High:186.12
52wk Low:122.14
Shares:102.00M
Float Shares:100.00M
Volume Ratio:0.86
T/O Rate:0.79%
Dividend:- -
Dividend Rate:- -
EPS(TTM):6.82
EPS(LYR):4.67
ROE:22.09%
ROA:11.70%
PB:4.34
PE(LYR):33.67

Loading ...

Neurocrine Amends 8-K to Update Pro Forma Financials for Soleno Acquisition

Reuters
·
Aug 01

Neurocrine Biosciences: Strong Q2 Execution, Expanded Pipeline, and Multi-Billion-Dollar Peak Sales Potential Support Buy Rating

TIPRANKS
·
Aug 01

Movement Alert|Neurocrine Biosciences Falls 9.92% in Regular Trading, Stock Under Pressure Despite Massive Q2 Earnings Beat

Market Focus
·
Aug 01

Neurocrine is Maintained at Overweight by Cantor Fitzgerald

Dow Jones
·
Jul 31

Analysts Are Bullish on Top Healthcare Stocks: Neurocrine (NBIX), Sanofi (SNYNF)

TIPRANKS
·
Jul 31

Analysts Offer Insights on Healthcare Companies: Neurocrine (NBIX), Regeneron (REGN) and PTC Therapeutics (PTCT)

TIPRANKS
·
Jul 31

Deutsche Bank Adjusts Neurocrine Biosciences Price Target to $190 From $170, Maintains Hold Rating

MT Newswires Live
·
Jul 31

Neurocrine price target raised to $222 from $200 at Guggenheim

TIPRANKS
·
Jul 31

Neurocrine Biosciences, Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Jul 31

Neurocrine Biosciences, Inc : Baird Raises Target Price to $225 from $186

THOMSON REUTERS
·
Jul 31

Neurocrine Director Leslie V. Norwalk Sells 1,250 Shares for $227,507.5

Reuters
·
Jul 31

Neurocrine Biosciences Q2 Adjusted EPS Beats Expectations, Revenue Rises on Product Portfolio Growth

Reuters
·
Jul 31

Neurocrine Biosciences Q2 Adjusted EPS USD 2.85 Vs. IBES Estimate USD 1.34

Reuters
·
Jul 31

Neurocrine Biosciences Q2 Adj. EPS $2.85 Beats $1.34 Estimate, Sales $959.000M Beat $883.259M Estimate

Benzinga Earnings
·
Jul 31

Neurocrine Biosciences, Inc: Ingrezza(Valbenazine) 2026 Net Sales Guidance Raised to $2.825 to $2.875 Billion

THOMSON REUTERS
·
Jul 31

Neurocrine Biosciences Q2 Product Sales USD 954.3 Million

THOMSON REUTERS
·
Jul 31

Neurocrine Biosciences Q2 EPS USD 1.39

THOMSON REUTERS
·
Jul 31

Jefferies Keeps Their Buy Rating on Neurocrine (NBIX)

TIPRANKS
·
Jul 30

Earning Preview: Neurocrine Biosciences this quarter’s revenue is expected to increase by 34.84%, and institutional views are bullish

Earnings Agent
·
Jul 24

Neurocrine Names Bret Paulson Senior Vice President of Market Access

Reuters
·
Jul 24